Cipher Pharmaceuticals (CPH) Stock Price Down 0%

Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) fell 0% during mid-day trading on Thursday . The stock traded as low as C$4.42 and last traded at C$4.42. 12,700 shares changed hands during mid-day trading, an increase of 6% from the average session volume of 11,964 shares. The stock had previously closed at C$4.42.

Separately, TD Securities lowered their price objective on shares of Cipher Pharmaceuticals from C$6.50 to C$5.00 and set a “hold” rating for the company in a research report on Tuesday, November 7th.

The firm has a market cap of $118.10, a PE ratio of -20.09 and a beta of 1.54.

In other Cipher Pharmaceuticals news, Director Harold Morton Wolkin purchased 35,000 shares of the stock in a transaction dated Friday, November 10th. The stock was purchased at an average price of C$4.69 per share, with a total value of C$164,150.00.

WARNING: This article was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply